Evidence map›Paper›PMID 41328527›Full record

ArticleHuman vaccines & immunotherapeutics2025

Identifying HPV vaccination research priorities for the US.

Noel T Brewer, Aditi Tomar, Rebecca Perkins, Gabrille Darville-Sanders, Marcie Fisher-Borne, Alison Footman, Shillpa Naavaal, Kristin Oliver, Debbie Saslow, Heather M Brandt

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noel T BrewerDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-2241-7002
Aditi TomarDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
Rebecca PerkinsDepartment of Obstetrics and Gynecology, Boston University School of Medicine/Boston Medical Center, Boston, MA, USA.
Gabrille Darville-SandersNational HPV Vaccination Roundtable, American Cancer Society, Atlanta, GA, USA.
Marcie Fisher-BorneOutcomes Research, Merck & Co., Inc., Rahway, NJ, USA.
Alison FootmanSexually Transmitted Infections, AVAC, New York, NY, USA.
Shillpa NaavaalDepartment of Pediatric Dentistry and Department of Dental Public Health and Policy, School of Dentistry, Virginia Commonwealth University, Richmond, VA, USA.
Kristin OliverDepartment of Pediatrics and Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Debbie SaslowNational HPV Vaccination Roundtable, American Cancer Society, Atlanta, GA, USA.
Heather M BrandtHPV Cancer Prevention Program, St. Jude Children's Research Hospital, Memphis, TN, USA.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Program Project – Improving Provider Announcement Communication Training (IMPACT)P01CA250989 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI QUEEN, TARA L · 2021 to 2025
$11.7M
NCI NIH HHS P01 CA250989NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

To guide researchers and funders, we sought to identify top priorities for research on increasing HPV vaccine coverage among US children ages 9-12 years. In Survey 1, 60 participants (researchers, health care professionals, and other stakeholders engaged in HPV vaccination research) viewed 57 research topics about increasing HPV vaccination coverage and provided additional topics. We integrated their suggestions into the list and condensed similar items to reach a list of 38 topics. In Survey 2, 230 participants identified their top ten research priorities. The top HPV vaccination research priorities and their corresponding themes were misinformation (chosen by 50% of respondents, from the theme of vaccine confidence), starting at age 9 years (48%, primary care), and single dose (48%, other). The top ten research priorities also included vaccine communication (40%, primary care), system-wide approach (39%, health system and payers), community settings (39%, alternative settings), immunization registries (38%, policy), geography and rurality (37%, populations), school mandates (37%, policy), and near elimination of HPV cancers (37%, other). The proportion of participants selecting topics within each theme varied between 15% for health system and payers to 32% for alternative settings. These research priorities highlight research areas likely to yield impactful strategies for increasing HPV vaccination. Focusing US HPV vaccine research on these topics can optimize resource allocation, inform evidence-based interventions, and support policymaking to enhance vaccine uptake.

Indexed as

Biomedical ResearchEvidence GapsPapillomavirus InfectionsPapillomavirus VaccinesVaccination CoverageChildFemaleHumansMaleSurveys and QuestionnairesUnited StatesVaccination HesitancyPapillomavirus VaccinesHPVResearch prioritiesvaccination

Identifiers

PMID41328527
PMCPMC12674246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.